Loading...
Loading...
VLON| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,385.0K |
| Operating I/L | -1,385.0K |
| Other Income/Expense | -198.0K |
| Interest Income | 0.0K |
| Pretax | -1,583.0K |
| Income Tax Expense | 602.0K |
| Net Income/Loss | -2,185.0K |
Vallon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of abuse-deterrent medications for central nervous system disorders. Its lead product candidate, ADAIR, is an abuse-deterrent oral formulation of immediate-release dextroamphetamine designed for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also working on ADMIR, an abuse-deterrent formulation of methylphenidate for ADHD treatment.
